Pancreatic Cancer Research

ResearcherJikei University School of MedicineNo recent work listed

Katsuhiko K. Yanaga

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8918-4720; OpenAlex author ID A5048098520. Sources: OpenAlex.

Their work

Papers
41 (first author 1, last author 36)
Trials
0
Grants
0
Labs led
1
Collaborators
43
Papers, trials and grants by year

2011: 3 papers · 2012: 3 papers · 2013: 8 papers · 2014: 1 paper · 2015: 5 papers · 2016: 6 papers · 2017: 2 papers · 2018: 5 papers · 2019: 3 papers · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper

Papers 41

  1. Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer. Co-author DOI 10.1371/journal.pone.0267623↗
  2. Phase II Study of Adjuvant Chemotherapy With Gemcitabine and Nafamostat Mesilate for Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000001767↗
  3. Suppression of lysosomal acid alpha-glucosidase impacts the modulation of transcription factor EB translocation in pancreatic cancer. Last author DOI 10.1111/cas.14921↗
  4. Splenic artery pseudoaneurysm following chemotherapy in a patient with pancreatic cancer: a case report. Last author DOI 10.1007/s12328-020-01137-0↗
  5. Prognostic Factors in Patients With Recurrent Pancreatic Cancer: A Multicenter Database Analysis. Last author DOI 10.21873/anticanres.13952↗
  6. Incidental abdominal lymph node metastases from a known breast cancer in resected specimen of invasive pancreatic ductal adenocarcinoma: report of a case. Last author DOI 10.1007/s13691-019-00382-6↗
  7. Claudin 7 as a possible novel molecular target for the treatment of pancreatic cancer. Last author DOI 10.1016/j.pan.2018.10.009↗
  8. Combination of Distance from Superior Mesenteric Artery and Serum CA19-9 as a Novel Prediction of Local Recurrence in Patients With Pancreatic Cancer Following… Last author DOI 10.21873/anticanres.13264↗
  9. Glycogen synthase kinase-3β activity plays a key role in the antitumor effect of nafamostat mesilate in pancreatic cancer cells. Last author DOI 10.1002/ags3.12025↗
  10. Pomalidomide promotes chemosensitization of pancreatic cancer by inhibition of NF-κB. Last author DOI 10.18632/oncotarget.24577↗
  11. Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer both in vitro and in vivo. Last author DOI 10.18632/oncotarget.24608↗
  12. Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy. Last author DOI 10.21873/anticanres.12485↗
  13. C-Reactive Protein-based Prognostic Measures Are Superior at Predicting Survival Compared with Peripheral Blood Cell Count-based Ones in Patients After Curativ… Last author DOI 10.21873/anticanres.13013↗
  14. Recombinant thrombomodulin suppresses tumor growth of pancreatic cancer by blocking thrombin-induced PAR1 and NF-κB activation. Last author DOI 10.1016/j.surg.2016.12.008↗
  15. Preoperative Platelet-to-Albumin Ratio Predicts Prognosis of Patients with Pancreatic Ductal Adenocarcinoma After Pancreatic Resection. Last author DOI 10.21873/anticanres.11378↗
  16. Isolating tape method is useful for an early judgment of curability during pancreaticoduodenectomy for pancreatic cancer. Last author DOI 10.1002/jhbp.381↗
  17. The C-reactive Protein to Albumin Ratio Predicts Long-Term Outcomes in Patients with Pancreatic Cancer After Pancreatic Resection. Last author DOI 10.1007/s00268-016-3491-4↗
  18. Dual inhibition of nuclear factor kappa-B and Mdm2 enhance the antitumor effect of radiation therapy for pancreatic cancer. Last author DOI 10.1016/j.canlet.2015.10.034↗
  19. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer. Last author DOI 10.1016/j.jss.2016.06.047↗
  20. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2. Co-author DOI 10.1158/0008-5472.can-15-2841↗
  21. Radical resection of T1 pancreatic adenocarcinoma with a pseudocyst of the tail due to acute obstructive pancreatitis: report of a case. Last author DOI 10.1186/s40792-016-0268-9↗
  22. Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer. First author DOI 10.1007/s00595-015-1129-z↗
  23. Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection. Last author DOI 10.1016/j.surg.2015.03.043↗
  24. Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation. Co-author DOI 10.1158/1535-7163.mct-14-0420↗
  25. Radical Resection of a Primarily Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy Using Gemcitabine, TS-1, and Nafamostat Mesilate; Report of a Ca… Last author DOI 10.9738/intsurg-d-13-00193.1↗
  26. Negative Impact of Preoperative Endoscopic Biliary Drainage on Prognosis of Pancreatic Ductal Adenocarcinoma After Pancreaticoduodenectomy. Last author PMID 26254410↗
  27. Postoperative peripheral absolute blood lymphocyte-to-monocyte ratio predicts therapeutic outcome after pancreatic resection in patients with pancreatic adenoc… Last author PMID 25202109↗
  28. Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pa… Co-author DOI 10.1002/ijc.27736↗
  29. Nuclear factor κB activity correlates with the progression and prognosis of pancreatic cancer in a mouse model. Last author DOI 10.1007/s00595-012-0279-5↗
  30. Combination chemotherapy of serine protease inhibitor nafamostat mesilate with oxaliplatin targeting NF-κB activation for pancreatic cancer. Last author DOI 10.1016/j.canlet.2013.01.019↗
  31. Inhibition of nuclear factor kappa-B enhances the antitumor effect of combination treatment with tumor necrosis factor-alpha gene therapy and gemcitabine for p… Last author DOI 10.1016/j.jamcollsurg.2012.09.016↗
  32. Phase II study of gemcitabine in combination with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. Last author DOI 10.1097/coc.0b013e31823a53b2↗
  33. Erlotinib-induced thrombocytosis in patients with recurrence of pancreatic cancer after distal pancreatectomy. Last author DOI 10.1097/mpa.0b013e31828cf976↗
  34. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life. Last author DOI 10.1186/1477-7819-11-3↗
  35. Negative impact of fresh-frozen plasma transfusion on prognosis of pancreatic ductal adenocarcinoma after pancreatic resection. Last author PMID 24023348↗
  36. Histopathologically proven autoimmune pancreatitis mimicking neuroendocrine tumor or pancreatic cancer. Last author DOI 10.1159/000336199↗
  37. Desensitization of NFκB for overcoming chemoresistance of pancreatic cancer cells to TNF-α or paclitaxel. Last author PMID 23155247↗
  38. Prognostic factors of unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy. Last author PMID 23155291↗
  39. Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition. Last author DOI 10.1007/s00534-011-0390-9↗
  40. Combination treatment using adenovirus vector-mediated tumor necrosis factor-alpha gene transfer and a NF-κB inhibitor for pancreatic cancer in mice. Last author DOI 10.1016/j.canlet.2011.02.036↗
  41. Combination paclitaxel and inhibitor of nuclear factor κB activation improves therapeutic outcome for model mice with peritoneal dissemination of pancreatic ca… Last author DOI 10.1097/mpa.0b013e31820b9257↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiroaki Shiba · 27 shared papers, 2011–2022 · strength 1.85
  2. Koichiro Haruki · 22 shared papers, 2011–2020 · strength 1.36
  3. Yoshihiro Shirai · 15 shared papers, 2014–2022 · strength 1.19
  4. Kenei Furukawa · 19 shared papers, 2011–2022 · strength 1.18
  5. Yuki Fujiwara · 21 shared papers, 2011–2020 · strength 1.13
  6. Tadashi Uwagawa · 20 shared papers, 2011–2019 · strength 1.11
  7. Takashi Horiuchi · 10 shared papers, 2015–2021 · strength 0.73
  8. Taro Sakamoto · 7 shared papers, 2015–2022 · strength 0.71
  9. Takeshi Gocho · 8 shared papers, 2012–2022 · strength 0.60
  10. Ryoga Hamura · 5 shared papers, 2018–2022 · strength 0.57
  11. Nobuhiro Saito · 6 shared papers, 2016–2021 · strength 0.49
  12. Shinji Onda · 5 shared papers, 2012–2022 · strength 0.43
  13. Tadashi Uwagawa · 3 shared papers, 2018–2022 · strength 0.37
  14. Toru Ikegami · 2 shared papers, 2021–2022 · strength 0.27
  15. Tomohiko Taniai · 2 shared papers, 2019–2021 · strength 0.24
  16. Fumitake Suzuki · 2 shared papers, 2016–2019 · strength 0.18
  17. Shuichi Fujioka · 3 shared papers, 2012–2016 · strength 0.16
  18. Norimitsu Okui · 2 shared papers, 2013–2019 · strength 0.13
  19. Masayuki Saruta · 1 shared paper, 2020 · strength 0.13
  20. Hironori Shiozaki · 1 shared paper, 2021 · strength 0.13
  21. Michinori Matsumoto · 1 shared paper, 2019 · strength 0.11
  22. Sadamu Homma · 1 shared paper, 2019 · strength 0.10
  23. Kyohei Abe · 1 shared paper, 2018 · strength 0.09
  24. Hiroshi Sugano · 1 shared paper, 2018 · strength 0.08
  25. Paul J. Chiao · 2 shared papers, 2012–2015 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.